Acutus Medical, Inc. (AFIB)

Market Cap	25.78M
Revenue (ttm)	15.76M
Net Income (ttm)	-85.99M
Shares Out	28.36M
EPS (ttm)	-4.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95,770
Open	0.91
Previous Close	0.906
Day's Range	0.87 - 0.93
52-Week Range	0.48 - 4
Beta	1.11
Analysts	Buy
Price Target	3.57 (+292.3%)
Earnings Date	Nov 10, 2022

About AFIB

Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and ...

• Industry: Medical Devices
• IPO Date: Aug 6, 2020
• Employees: 338
• Stock Exchange: NASDAQ
• Ticker Symbol: AFIB

Financial Performance

In 2021, Acutus Medical's revenue was $17.26 million, an increase of 103.96% compared to the previous year's $8.46 million. Losses were -$117.68 million, 15.4% more than in 2020.

Analyst Forecast

According to 12 analysts, the average rating for AFIB stock is "Buy." The 12-month stock price forecast is 3.57, which is an increase of 292.31% from the latest price.

Price Target

$3.57

(292.31% upside)

Analyst Consensus: Buy